Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IYAD S HAMARNEH

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1427268259
CMS profile
109889
Location
PRESCOTT, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,725.09

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,626.09 77
Education $99.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IYAD S HAMARNEH

NPI 1427268259 · CMS profile ID 109889

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PRESCOTT, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427268259?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IYAD S HAMARNEH, NPI 1427268259, CMS profile ID 109889. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427268259?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). IYAD S HAMARNEH, NPI 1427268259, CMS profile ID 109889. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427268259?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
IYAD S HAMARNEH, NPI 1427268259, CMS profile ID 109889, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1427268259?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $1,725.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Karyopharm Therapeutics Inc. $13.2505/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145530865 CMS
E.R. Squibb & Sons, L.L.C. $14.2505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101641346 CMS
PFIZER INC. $17.6305/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131413876 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.4505/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086189216 CMS
Aveo Pharmaceuticals, Inc. $99.0004/29/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143478898 CMS
Incyte Corporation $26.5404/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141177680 CMS
PFIZER INC. $21.8504/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131311738 CMS
Janssen Biotech, Inc. $23.1004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078281155 CMS
Genentech USA, Inc. $22.3704/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133023099 CMS
ABBVIE INC. $21.0404/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103868341 CMS
Celgene Corporation $20.9904/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101166714 CMS
E.R. Squibb & Sons, L.L.C. $21.8804/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101641328 CMS
ARRAY BIOPHARMA INC $20.1504/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131404029 CMS
Genmab U.S., Inc. $26.0104/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126827352 CMS
Karyopharm Therapeutics Inc. $13.2903/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145530862 CMS
Mirati Therapeutics, Inc. $13.4503/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117173910 CMS
Pharmacosmos Therapeutics Inc. $25.0703/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154822259 CMS
ABBVIE INC. $19.2003/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103868339 CMS
E.R. Squibb & Sons, L.L.C. $13.6602/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101641254 CMS
Genmab U.S., Inc. $27.4502/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126827346 CMS
PFIZER INC. $20.3902/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131283893 CMS
PFIZER INC. $17.8102/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131141182 CMS
E.R. Squibb & Sons, L.L.C. $17.7001/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101641250 CMS
Celgene Corporation $16.8901/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101166704 CMS
Incyte Corporation $18.7701/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141253036 CMS
PFIZER INC. $22.7401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130982331 CMS
AstraZeneca Pharmaceuticals LP $18.8601/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104369513 CMS
Blueprint Medicines Corporation $21.3801/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147441042 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,989.75 95
PY2020 $300.74 14
PY2021 $2,522.55 7
PY2022 $6,058.60 18
PY2023 $793.31 30
PY2024 $1,725.09 78
PY2025 $1,354.06 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $576,327.32 246
PY2024 Principal investigator $206,411.16 53
PY2023 Principal investigator $55,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

246 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,493.36 12/31/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185555699
Principal investigator 1 Daiichi Sankyo Inc. $90.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387989
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388007
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388025
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 12/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363539
Principal investigator 1 Daiichi Sankyo Inc. $200.00 12/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363567
Principal investigator 1 Daiichi Sankyo Inc. $54.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387975
Principal investigator 1 Daiichi Sankyo Inc. $66.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387977
Principal investigator 1 Daiichi Sankyo Inc. $2,630.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387979
Principal investigator 1 Daiichi Sankyo Inc. $64.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387981
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387983
Principal investigator 1 Daiichi Sankyo Inc. $50.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387985
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387987
Principal investigator 1 Daiichi Sankyo Inc. $42.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387991
Principal investigator 1 Daiichi Sankyo Inc. $55.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387993
Principal investigator 1 Daiichi Sankyo Inc. $555.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387995
Principal investigator 1 Daiichi Sankyo Inc. $40.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387997
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387999
Principal investigator 1 Daiichi Sankyo Inc. $55.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388001
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388003
Principal investigator 1 Daiichi Sankyo Inc. $555.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388005
Principal investigator 1 Daiichi Sankyo Inc. $59.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388009
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388011
Principal investigator 1 Daiichi Sankyo Inc. $51.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388013
Principal investigator 1 Daiichi Sankyo Inc. $65.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388015
Principal investigator 1 Daiichi Sankyo Inc. $555.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388017
Principal investigator 1 Daiichi Sankyo Inc. $55.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388019
Principal investigator 1 Daiichi Sankyo Inc. $555.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388021
Principal investigator 1 Daiichi Sankyo Inc. $53.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388023
Principal investigator 1 Daiichi Sankyo Inc. $56.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363531
Principal investigator 1 Daiichi Sankyo Inc. $418.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363533
Principal investigator 1 Daiichi Sankyo Inc. $47.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363535
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363537
Principal investigator 1 Daiichi Sankyo Inc. $418.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363541
Principal investigator 1 Daiichi Sankyo Inc. $418.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363543
Principal investigator 1 Daiichi Sankyo Inc. $46.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363545
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363547
Principal investigator 1 Daiichi Sankyo Inc. $383.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363549
Principal investigator 1 Daiichi Sankyo Inc. $2,808.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363553
Principal investigator 1 Daiichi Sankyo Inc. $2,808.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363555
Principal investigator 1 Daiichi Sankyo Inc. $4,514.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363557
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363561
Principal investigator 1 Daiichi Sankyo Inc. $47.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363565
Principal investigator 1 Daiichi Sankyo Inc. $50.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363569
Principal investigator 1 Daiichi Sankyo Inc. $45.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363571
Principal investigator 1 Daiichi Sankyo Inc. $36.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363573
Principal investigator 1 Daiichi Sankyo Inc. $34.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363575
Principal investigator 1 Daiichi Sankyo Inc. $43.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363577
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363579
Principal investigator 1 Daiichi Sankyo Inc. $54.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363581
Principal investigator 1 Daiichi Sankyo Inc. $47.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363583
Principal investigator 1 Daiichi Sankyo Inc. $55.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363585
Principal investigator 1 Daiichi Sankyo Inc. $1,336.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363587
Principal investigator 1 Daiichi Sankyo Inc. $43.00 11/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363589
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 11/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387425
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 11/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387427
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387947
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223363383
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363551
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 10/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363559
Principal investigator 1 Daiichi Sankyo Inc. $200.00 10/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363563
Principal investigator 1 PFIZER INC. $957.00 10/15/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228726424
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387927
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387929
Principal investigator 1 Daiichi Sankyo Inc. $555.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387931
Principal investigator 1 Daiichi Sankyo Inc. $13,320.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387933
Principal investigator 1 Daiichi Sankyo Inc. $555.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387935
Principal investigator 1 Daiichi Sankyo Inc. $450.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387937
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387939
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387941
Principal investigator 1 Daiichi Sankyo Inc. $555.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387943
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387945
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387949
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387951
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387953
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387955
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387957
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387959
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387961
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387963
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387965
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387967
Principal investigator 1 Daiichi Sankyo Inc. $450.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387969
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387971
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387973
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387889
Principal investigator 1 Daiichi Sankyo Inc. $301.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387915
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 09/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387867
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387869
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 09/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387891
Principal investigator 1 Daiichi Sankyo Inc. $236.00 09/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387901
Principal investigator 1 Daiichi Sankyo Inc. $236.00 09/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387903
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 09/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387909
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387911
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 09/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387913
Principal investigator 1 PFIZER INC. $1,125.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228757764
Principal investigator 1 Daiichi Sankyo Inc. $236.00 09/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387863
Principal investigator 1 Daiichi Sankyo Inc. $555.00 09/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387879
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 09/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387897
Principal investigator 1 Daiichi Sankyo Inc. $236.00 09/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387899
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387907
Principal investigator 1 Daiichi Sankyo Inc. $90.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387865
Principal investigator 1 Daiichi Sankyo Inc. $90.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387871
Principal investigator 1 Daiichi Sankyo Inc. $47.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387873
Principal investigator 1 Daiichi Sankyo Inc. $47.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387875
Principal investigator 1 Daiichi Sankyo Inc. $47.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387877
Principal investigator 1 Daiichi Sankyo Inc. $301.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387881
Principal investigator 1 Daiichi Sankyo Inc. $90.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387883
Principal investigator 1 Daiichi Sankyo Inc. $47.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387885
Principal investigator 1 Daiichi Sankyo Inc. $55.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387887
Principal investigator 1 Daiichi Sankyo Inc. $90.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387893
Principal investigator 1 Daiichi Sankyo Inc. $47.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387895
Principal investigator 1 Daiichi Sankyo Inc. $47.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387905
Principal investigator 1 Daiichi Sankyo Inc. $301.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387917
Principal investigator 1 Daiichi Sankyo Inc. $90.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387919
Principal investigator 1 Daiichi Sankyo Inc. $555.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387921
Principal investigator 1 Daiichi Sankyo Inc. $55.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387923
Principal investigator 1 Daiichi Sankyo Inc. $47.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387925
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,150.00 08/31/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185555703
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387421
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387423
Principal investigator 1 Daiichi Sankyo Inc. $47.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387851
Principal investigator 1 Daiichi Sankyo Inc. $47.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387853
Principal investigator 1 Daiichi Sankyo Inc. $47.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387855
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387857
Principal investigator 1 Daiichi Sankyo Inc. $47.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387861
Principal investigator 1 Daiichi Sankyo Inc. $10,656.00 08/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387859
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 07/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387419
Principal investigator 1 PFIZER INC. $957.00 07/15/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745450
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,300.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185555705
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 06/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387413
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363449
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363469
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363457
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 06/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363529
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 06/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387415
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 06/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387417
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/28/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363483
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/28/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363485
Principal investigator 1 PFIZER INC. $1,125.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228772944
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363447
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363451
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363455
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363459
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363461
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363463
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363465
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363471
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363473
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363479
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363481
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363513
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363515
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363517
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363519
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363523
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363525
Principal investigator 1 Daiichi Sankyo Inc. $77.00 05/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363527
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/12/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363509
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/12/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363511
Principal investigator 1 AstraZeneca Pharmaceuticals LP $28,500.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185555691
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,712.05 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185555697
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,650.00 04/30/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185555695
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,834.75 04/30/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185555701
Principal investigator 1 Daiichi Sankyo Inc. $13,320.00 04/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387845
Principal investigator 1 Eli Lilly and Company $1,110.00 04/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187893530
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387833
Principal investigator 1 Daiichi Sankyo Inc. $555.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387835
Principal investigator 1 Daiichi Sankyo Inc. $236.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387837
Principal investigator 1 Daiichi Sankyo Inc. $236.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387839
Principal investigator 1 Daiichi Sankyo Inc. $236.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387841
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387843
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387847
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387849
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223363381
Principal investigator 1 Daiichi Sankyo Inc. $1,204.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363453
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363467
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363487
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363489
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363491
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363493
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363495
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363497
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363499
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363501
Principal investigator 1 Daiichi Sankyo Inc. $200.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363503
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363505
Principal investigator 1 Daiichi Sankyo Inc. $418.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363507
Principal investigator 1 Daiichi Sankyo Inc. $46.00 04/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363521
Principal investigator 1 PFIZER INC. $957.00 04/15/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747077
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363475
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363477
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387407
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387409
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387411
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/25/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363405
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/25/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363411
Principal investigator 1 Daiichi Sankyo Inc. $555.00 03/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387815
Principal investigator 1 Daiichi Sankyo Inc. $555.00 03/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387817
Principal investigator 1 Genentech, Inc. $1,500.00 03/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC No dispute reported 06/30/2026 1211676384
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363419
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363421
Principal investigator 1 Daiichi Sankyo Inc. $418.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363423
Principal investigator 1 Daiichi Sankyo Inc. $201.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363425
Principal investigator 1 Daiichi Sankyo Inc. $200.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363427
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363429
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363431
Principal investigator 1 Daiichi Sankyo Inc. $201.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363437
Principal investigator 1 Daiichi Sankyo Inc. $201.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363439
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 03/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363441
Principal investigator 1 Daiichi Sankyo Inc. $236.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387819
Principal investigator 1 Daiichi Sankyo Inc. $555.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387823
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387825
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387827
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387821
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387829
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387831
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/04/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363407
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/04/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363409
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 02/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363387
Principal investigator 1 Daiichi Sankyo Inc. $418.00 02/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363389
Principal investigator 1 Daiichi Sankyo Inc. $200.00 02/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363393
Principal investigator 1 Daiichi Sankyo Inc. $418.00 02/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363415
Principal investigator 1 Daiichi Sankyo Inc. $200.00 02/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363433
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 02/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363443
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387187
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/12/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363401
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/12/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363403
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,400.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185555693
Principal investigator 1 Eli Lilly and Company $60,941.00 02/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187892746
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/23/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363399
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/23/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363445
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,934.25 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185555707
Principal investigator 1 Daiichi Sankyo Inc. $10,415.00 01/16/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388275
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223363379
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363395
Principal investigator 1 Daiichi Sankyo Inc. $4,514.00 01/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363397
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363413
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 01/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363417
Principal investigator 1 Daiichi Sankyo Inc. $418.00 01/15/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363435
Principal investigator 1 Eli Lilly and Company $3,066.00 01/15/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES PC HOPE
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187874935
Principal investigator 1 Eli Lilly and Company $92,451.00 01/15/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES PC HOPE
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187877169
Principal investigator 1 PFIZER INC. $957.00 01/15/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745721
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/06/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363385
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/06/2025 Non-covered Recipient Entity
Arizona Oncology Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223363391
Principal investigator 1 Eli Lilly and Company $0.73 01/06/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES PC HOPE
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187876891